No Data
No Data
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Support
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Truist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
No Data
Papanice : 今天飞吗?
TrytosaveabitOP Papanice: Not sure what it’s going to do yet! Got to see if it gets any volume? GL
Papanice TrytosaveabitOP: 你说能就能了, 吸引力法则 哈哈哈
TrytosaveabitOP Papanice: Hehehe!